Climb Bio, Inc. (NASDAQ:CLYM) Receives $9.00 Consensus Price Target from Analysts

Key Points

• Climb Bio, Inc. (NASDAQ:CLYM) has received an average recommendation of "Buy" from six brokerages, with four analysts rating it as a buy and two as a strong buy.
• The company has a 12-month price target of $9.00 set by analysts, with recent coverage indicating optimistic ratings from firms like Baird and Oppenheimer.
• As of the latest earnings report, Climb Bio reported an EPS of -$0.13, exceeding the consensus estimate of -$0.19, and is currently priced at $2.47 with a market capitalization of $167.37 million.

Shares of Climb Bio, Inc. (NASDAQ:CLYM - Get Free Report) have earned a consensus rating of "Buy" from the six research firms that are covering the stock, Marketbeat.com reports. Four research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $9.00.

A number of research firms have issued reports on CLYM. Oppenheimer started coverage on shares of Climb Bio in a report on Friday, June 6th. They set an "outperform" rating and a $10.00 target price on the stock. BTIG Research started coverage on shares of Climb Bio in a report on Thursday, May 22nd. They issued a "buy" rating on the stock. Robert W. Baird started coverage on shares of Climb Bio in a report on Friday, August 15th. They issued an "outperform" rating and a $9.00 price objective on the stock. Finally, Baird R W upgraded shares of Climb Bio to a "strong-buy" rating in a report on Friday, August 15th.

Climb Bio Stock Performance

Shares of CLYM stock traded down $0.15 on Tuesday, reaching $2.25. 404,709 shares of the company were exchanged, compared to its average volume of 578,098. The company has a market cap of $152.46 million, a price-to-earnings ratio of -3.21 and a beta of -0.05. The business has a 50-day moving average price of $1.83 and a 200 day moving average price of $1.46. Climb Bio has a 1 year low of $1.05 and a 1 year high of $8.79.

Climb Bio (NASDAQ:CLYM - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.06. As a group, equities analysts anticipate that Climb Bio will post -1.57 earnings per share for the current year.

Institutional Investors Weigh In On Climb Bio

Hedge funds and other institutional investors have recently modified their holdings of the company. RA Capital Management L.P. purchased a new position in shares of Climb Bio in the 1st quarter valued at $38,332,000. Affinity Asset Advisors LLC purchased a new position in shares of Climb Bio in the 1st quarter valued at $1,830,000. Peapod Lane Capital LLC purchased a new position in shares of Climb Bio in the 1st quarter valued at $676,000. Nan Fung Trinity HK Ltd. purchased a new position in shares of Climb Bio in the 2nd quarter valued at $575,000. Finally, Allostery Investments LP purchased a new position in shares of Climb Bio in the 1st quarter valued at $299,000. 69.76% of the stock is currently owned by institutional investors and hedge funds.

Climb Bio Company Profile

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.